The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ...